Conditions: Psoriasis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 84
Healthy volunteers: yes

Brief summary:
This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose.

Detailed description:
This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

Arms:
arm 1: Placebo treatment arm 2: 140 mg SC PsO arm 3: 350 mg SC PsO arm 4: 700 mg IV PsO

Interventions: intervention 1: 700 mg IV intervention 2: 350 mg SC intervention 3: Placebo intervention 4: 140 mg SC
Intervention descriptions: intervention 1: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B). intervention 2: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B). intervention 3: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B). intervention 4: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

Protocol document: